Pembrolizumab

Also known as KEYTRUDA and KEYTRUDA®.

Latest news on pembrolizumab

5 November 2026
Johnson & Johnson wins FDA accelerated approval for RYBREVANT FASPRO in recurrent/metastatic HNSCC

Subcutaneous bispecific (amivantamab + hyaluronidase) approved for adults with recurrent/metastatic head and neck squamous cell carcinoma after platinum and anti‑PD‑(L)1 therapy.

5 November 2026
Genmab nine-month 2026 results: revenue up 22%, epcoritamab approved, Phase‑3 readouts positive

Revenue rose 22% to $3,238m; epcoritamab approved in Europe and Japan; two Phase‑3 starts for petosemtamab in CRC; multiple Phase‑3 topline readouts were positive.

28 October 2026
Genmab: Petosemtamab plus pembrolizumab halves mortality in PD‑L1+ R/M HNSCC in Phase 3 interim readout

First interim IDMC readout from LiGeR‑HN1 shows a 50% reduction in risk of death and a >3‑fold increase in objective response for the combination versus pembrolizumab alone.

26 October 2026
Genmab: Petosemtamab plus pembrolizumab yields 28.2‑month median OS in 1L PD‑L1+ r/m HNSCC

Combination therapy produced 28.2‑month median OS, 63% ORR and 9.0‑month mPFS in first‑line PD‑L1+ recurrent/metastatic head and neck cancer, with responses across HPV status.

26 October 2026
Merck: KEYTRUDA monotherapy lowers progression or death risk 43% in dMMR advanced or recurrent endometrial cancer

Phase 3 KEYNOTE‑C93: pembrolizumab alone extended median PFS to 38.2 vs 8.4 months versus platinum doublet; results presented at ESMO and published in The Lancet.

25 October 2026
Johnson & Johnson: RYBREVANT FASPRO shows high response in first‑line advanced head and neck cancer

Cohort 5 reported 77% confirmed ORR (14% CR) in non‑HPV HNSCC with subcutaneous amivantamab + pembrolizumab and carboplatin; median follow‑up 10.6 months; safety consistent with known profiles.

25 October 2026
Lilly's olomorasib shows durable first-line activity in KRAS G12C NSCLC

Durable PFS and DOR not reached with immunotherapy combo; chemoimmunotherapy combo showed 62% ORR and 14.5‑month median DOR in first-line KRAS G12C NSCLC.

25 October 2026
Roche’s divarasib shows superior survival vs first‑generation KRAS G12C inhibitors in NSCLC

Phase III Krascendo 1: divarasib reduced risk of progression/death by 42% and risk of death by 44%; median OS ~17.7 vs 12.0 months; ORR 58% vs 32%; manageable safety.

23 October 2026
Johnson & Johnson presents >25 solid tumor abstracts and new clinical data at ESMO 2026

New clinical results include first-in-human data for oral RIPTAC JNJ-6143 in mCRPC, late-breaking PROTEUS Phase 3 prostate results, and expanded RYBREVANT FASPRO datasets across lung and head & neck cancers.

22 October 2026
Merck and Moderna present Phase 3 INTerpath‑001: intismeran + KEYTRUDA reduces recurrence in resected stage IIB–IV melanoma

Intismeran plus pembrolizumab cut risk of recurrence or death 42% overall and 58% after six months; distant‑metastasis‑free survival also improved; safety profile consistent.